CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 42 enrolled
Drug / intervention
Donanemabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05567159
NCT05567159Phase 1Completed
CompareCT.gov

A Phase 1, Open-Label Study to Characterize the Pharmacokinetics of Donanemab Following Intravenous Doses in Healthy Participants

Eli Lilly and Company·interventional·Posted Oct 5, 2022·Updated Oct 4, 2024

In Brief

A Phase 1 clinical trial evaluating Donanemab for Healthy. Completed, enrolled 42 participants across 1 site.

Detailed Summary

The main purpose of this study is to assess how fast donanemab (LY3002813) gets into the blood stream and how long it takes the body to remove it when administered as single dose in healthy participants. The study will also evaluate the safety and tolerability of donanemab. The study will last up to approximately 22 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedOct 5, 2022
Enrollment StartOct 4, 2022
Primary CompletionJul 14, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.7 years ago

Interventions

Donanemabdrug

Administered IV.